Cryoport (CYRX) offers leveraged upside to cell and gene therapy commercialization, with a 70% clinical trial foothold, post-divestiture margin improvement, and enough cash to retire its 2026 converts without dilution.
Overview
Cryoport Inc. is a specialized life sciences cold-chain platform built around transporting and preserving highly sensitive biologic materials, with a particularly strong position in cell and gene therapy. The company operates across logistics, biostorage, cryopreservation, and cryogenic equipment, and its competitive edge comes from regulatory integration, validated shipping lanes, proprietary telemetry, and quality systems such as Chain of Compliance, Smartpak, Veri-Clean, and ISO 21973 certification. **The core investment case is that Cryoport already supports roughly 70% of global cell and gene therapy clinical trials, creating a powerful pipeline-to-commercial conversion opportunity as therapies advance toward approval.** In Q1 2026, revenue rose 16.5% year over year to $47.8 million, beating consensus by 6.5%, while management raised full-year 2026 revenue guidance to $192 million-$196 million, implying 9%-11% organic growth. **The June 2025 CRYOPDP divestiture to DHL structurally improved the story by bringing in about $200 million of cash, removing lower-margin courier revenue, and reinforcing a more capital-light, higher-margin model.** Although Cryoport remains GAAP unprofitable, adjusted EBITDA improved to -$0.6 million from -$2.8 million, and management expects positive adjusted EBITDA in H2 2026. With the stock trading around 4.41x sales and commercial CGT revenue growing 26% year over year in Q1 2026, the report frames CYRX as an asymmetric long-term play on CGT scale-up.